Compare Cassava Sciences Inc (FLNA) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Cassava Sciences Inc trades at $0.81 (market cap $39.40M), while YieldMax TSLA Option Income Strategy ETF trades at $22.59 (market cap $697.51M). The key difference: YieldMax TSLA Option Income Strategy ETF is far larger — about 17.7× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 338,271). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and YieldMax TSLA Option Income Strategy ETF for 43 Days on average.
| FLNA | TSLY | |
|---|---|---|
Market Cap | $39.40M | $697.51M |
Volume | 759,018 | 338,271 |
Sector | Health | Income / Options Overlay |
52-Week High | $4.64 | $43.35 |
52-Week Low | $0.68 | $20.49 |
Typical Hold Time | 37 Days | 43 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
TSLY trades at $22.60, down 0.44% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.21-0.23, though recent analysis highlights concerns about capital erosion despite high yields. Technical indicators show support at $22 and resistance at $23, with neutral oscillators suggesting limited momentum.
While TSLY offers attractive income generation through its option income strategy, the fund faces structural limitations in capturing Tesla's upside potential. Recent downgrades to Hold reflect diminished return prospects amid Tesla's volatility changes. The primary risk remains the trade-off between high distributions and long-term capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
